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Glutamine has been implicated as an immunomodu-
latory nutrient, but how glutamine uptake ismediated
during T cell activation is poorly understood. We
have shown that naive T cell activation is coupled
with rapid glutamine uptake, which depended on
the amino acid transporter ASCT2. ASCT2 deficiency
impaired the induction of T helper 1 (Th1) and Th17
cells and attenuated inflammatory T cell responses
in mouse models of immunity and autoimmunity.
Mechanistically, ASCT2 was required for T cell re-
ceptor (TCR)-stimulated activation of the metabolic
kinase mTORC1. We have further shown that TCR-
stimulated glutamine uptake andmTORC1 activation
also required a TCR signaling complex composed of
the scaffold protein CARMA1, the adaptor molecule
BCL10, and the paracaspase MALT1. This function
was independent of IKK kinase, a major downstream
target of the CARMA1 complex. These findings high-
light a mechanism of T cell activation involving
ASCT2-dependent integration of the TCR signal
and a metabolic signaling pathway.
INTRODUCTION
T cells serve as a central cellular component of adaptive immu-
nity. Following their maturation in the thymus, naive T cells
circulate in the periphery searching for specific antigens. Upon
activation by an antigen, naive CD4+ T cells proliferate and differ-
entiate into various subsets of T helper (Th) cells, including Th1,
Th2, and Th17 cells, which produce different cytokines and
mediate distinct effector functions (Zhu et al., 2010). In addition
to their critical involvement in immune responses against infec-
tions, Th1 and Th17 cells also play an important role in mediating
the pathogenesis of autoimmune inflammatory disorders, such
as experimental autoimmune encephalomyelitis (EAE) (Simmons
et al., 2013). The activated naive CD4+ T cells can also produce692 Immunity 40, 692–705, May 15, 2014 ª2014 Elsevier Inc.Foxp3+ regulatory T (Treg) cells with immunosuppressive func-
tions (Zhu et al., 2010). Thus, deregulated CD4+ T cell activation
and differentiation are a hallmark of autoimmune and inflamma-
tory diseases.
The activation and differentiation of T cells require signals eli-
cited by the T cell receptor (TCR) and costimulatory receptors,
particularly CD28, as well as signals stimulated by various cyto-
kines (Yamane and Paul, 2012). Moreover, emerging evidence
suggests that proper activation and differentiation of T cells are
also influenced by other signals derived from the immune micro-
environment, including metabolic stimuli (MacIver et al., 2013;
van der Windt and Pearce, 2012; Waickman and Powell, 2012).
A signaling molecule that integrates the environmental stimuli
to mediate T cell function is protein kinase mammalian target
of rapamycin (mTOR) (Chi, 2012; Waickman and Powell, 2012).
mTOR exists in two major signaling complexes, mTOR complex
1 (mTORC1) and mTORC2, which differ in their mechanism of
activation and signaling functions (Sarbassov et al., 2005). In
particular, mTORC1 phosphorylates two regulators of protein
synthesis, the S6 kinase 1 (S6K1, also known as p70 S6K) and
4 elongation factor-binding protein 1 (4E-BP1), thereby promot-
ing cell growth and proliferation (Fingar et al., 2002; Holz and
Blenis, 2005; Sarbassov et al., 2005). In T cells, mTORC1 is acti-
vated by both the TCR and CD28 signals and environmental
cues, including those derived amino acids (Chi, 2012). Amino
acids activate mTORC1 by inducing its translocation to lyso-
somal membranes in a mechanism that depends on a specific
regulator complex (Sancak et al., 2010). Ligation of TCR and
CD28 triggers the activation of mTORC1, which is important
for preventing T cell anergy (Gorentla et al., 2011; Zheng et al.,
2007). The TCR signal induces leucine uptake via a system L
amino acid transporter, composed of Slc7a5 and CD98, which
is important for activation of mTORC1 andmetabolic reprogram-
ming of T cells (Sinclair et al., 2013).
Glutamine is the most abundant amino acid in the blood-
stream and has been implicated as an immunomodulatory
nutrient (Karinch et al., 2001; Lund and Williamson, 1985; News-
holme, 2001). It is generally thought that glutamine, although
not an essential amino acid, provides fuel for rapidly dividing
cells, such as lymphocytes and enterocytes. However, precisely
how glutamine regulates immune responses is incompletely
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porters have been shown to mediate glutamine transportation
in cancer cell lines (McGivan and Bungard, 2007), whether any
of them is required for glutamine uptake in T cells is obscure.
In the present study, we found that stimulation of naive CD4+
T cells via the TCR and CD28 triggered rapid uptake of
glutamine. Furthermore, glutamine was critically required for
naive CD4+ T cell differentiation to Th1 and Th17 inflammatory
T cells but not to Th2 or Treg cells. By employing a gene-target-
ing approach, we identified the amino acid transporter ASCT2
(also known as Slc1a5) (Utsunomiya-Tate et al., 1996) as a
crucial mediator of TCR-stimulated glutamine uptake in naive
CD4+ T cells. Although ASCT2 was dispensable for T cell prolif-
eration and interleukin-2 (IL-2) induction, it was essential for the
generation of Th1 and Th17 cells under both in vitro and in vivo
conditions. Consistently, Slc1a5–/– mice were refractory to in-
duction of the T cell-dependent autoimmunity, EAE. We also
obtained genetic evidence that ASCT2 coupled the TCR and
CD28 signals to the activation of the metabolic kinase mTORC1.
Thus, our data suggest a mechanism of T cell activation that
involves ASCT2-dependent integration of the TCR and CD28
signals with glutamine uptake and activation of a metabolic
signaling pathway.
RESULTS
ASCT2 Regulates Lymphocyte Homeostasis
To study the physiological function of ASCT2, we employed a
conventional gene-targeting approach (see Figures S1A–S1C
available online). The Slc1a5–/– mice were born with expected
Mendelian ratios and did not show obvious abnormalities in
growth or survival (data not shown). These mutant animals also
had normal thymocyte development, as revealed by the compa-
rable frequencies of thymocyte subpopulations and total thymo-
cyte numbers in the Slc1a5+/+ and Slc1a5–/– mice (Figures S1D
and S1E).
To examine the role of ASCT2 in regulating peripheral T cell
homeostasis, we examined the frequency of T cells in the spleen
of the Slc1a5+/+ and Slc1a5–/– mice. At young ages (6–7 weeks),
the Slc1a5–/– mice had a moderate, but statistically significant,
increase in the frequency of T cells and decrease in the fre-
quency of B cells in the spleen (Figure S2A). This result was
not because of an increase in the number of T cells but rather
due to the reduced B cell numbers (Figure S2B). The frequency
and absolute number of memory and naive CD4+ T cells
were also largely comparable between young Slc1a5+/+ and
Slc1a5–/– mice (Figures S2C and S2D). However, older ASCT2-
deficient mice (5–6 months) had reduced frequency and
numbers of CD4+ T cells (Figure 1A), reflecting a profound reduc-
tion in the CD44hiCD62Llo memory population (Figure 1B).
In contrast, the Slc1a5–/– mice had increased frequency and
normal numbers of the CD44loCD62Lhi naive CD4+ T cells
compared to the Slc1a5+/+ mice (Figure 1B). No obvious abnor-
malities were found in CD8+ T cells (Figure 1A). Among the CD4+
memory T cells, there was a dramatic reduction in the percent-
age of interferon-g (IFN-g)-producing Th1 and IL-17-producing
Th17 cells; however, the ASCT2 deficiency did not alter the fre-
quency of Treg cells (Figure 1C). These results suggest that
although ASCT2 is dispensable for thymocyte development, itis required for regulating the homeostasis and possibly the differ-
entiation of peripheral CD4+ T cells.
ASCT2 Is Required for Naive CD4+ T Cell Differentiation
In Vitro
The reduction in memory T cell population, particularly Th1 and
Th17 cells, in the older Slc1a5–/– mice prompted us to examine
the role of ASCT2 in the regulation of T cell activation and differ-
entiation. We purified naive CD4+ T cells from young Slc1a5+/+
and Slc1a5–/– mice, because the young mutant mice had no
obvious phenotype in T cell homeostasis (Figures S2C and
S2D). In response to stimulation by the TCR inducer anti-CD3
and the costimulator anti-CD28, the Slc1a5+/+ and Slc1a5–/–
T cells displayed similar abilities to proliferate and produce the
T cell growth factor IL-2 (Figures 2A and 2B). However, in vitro
CD4+ T cell differentiation assays revealed a profound defect
of the Slc1a5–/– naive CD4+ T cells in the generation of the
IFN-g-producing Th1 and the IL-17-producing Th17 cells,
although not in the generation of the Foxp3+ Treg cells, as deter-
mined by intracellular cytokine staining and flow cytometry
assays (Figures 2C and 2D). This defect was due to the reduced
percentage of Th1 and Th17 cells rather than alterations in gene
expression on a single-cell basis, as shown by the comparable
median florescence intensity (MFI) of IL-17 and IFN-g on gated
Slc1a5+/+ andSlc1a5–/– Th17 and Th1 cells (Figure S3A). Further-
more, the proliferation and survival ability of these different
T cells was also similar (Figure S3B). The differentiation defect
of the Slc1a5–/– naive CD4+ T cells was also detected in parallel
quantitative PCR (qPCR) assays and ELISA, based on the detec-
tion of IFN-g and IL-17 induction at the RNA and protein levels,
respectively (Figures 2E and 2F). These latter assays also re-
vealed attenuated induction of the genes encoding the Th1-
and Th17 cell-lineage transcription factors, T-bet and RORgt
(Figure 2E). In contrast to the defective production of Th1 and
Th17 cells, the generation of Th2 cells was not reduced, but
rather enhanced, in the Slc1a5–/– T cells (Figures 2E and 2F).
Taken together with the reduced Th1 and Th17 cell frequencies
in olderSlc1a5–/– mice (Figure 1), these results suggest an impor-
tant role for ASCT2 in the regulation of naive CD4+ T cell differen-
tiation to the Th1 and Th17 cell subsets.
We next examined whether ASCT2 deficiency affected the
expression of other amino acid transporters. In Slc1a5+/+ naive
CD4+ T cells, TCR and CD28 signals induced the expression of
ASCT2, as well as several other amino acid transporters,
including SNAT1, SNAT2, Slc7a5, and CD98 (Figure S3C).
ASCT2mRNAwas undetectable in theSlc1a5–/– T cells, confirm-
ing null phenotype at the RNA level (Figure S3B). Moreover, the
loss of ASCT2 did not inhibit the induction of the other amino
acid transporters, although it moderately reduced the basal level
of CD98 mRNA (Figure S3C). To examine whether the effect of
ASCT2 deficiency on CD4+ T cell differentiation was direct, we
transduced Slc1a5+/+ and Slc1a5–/– CD4+ T cells with a GFP-ex-
pressing retroviral vector or the same vector encoding ASCT2.
Expression of exogenous ASCT2 moderately promoted Th1
and Th17 cell differentiation (Figure S3D). More importantly,
reconstitution of Slc1a5–/– T cells with exogenous ASCT2 largely
rescued their defect in Th1 and Th17 cell differentiation (Fig-
ure S3D). Parallel experiments revealed that transduction of
SNAT1, another amino acid transporter implicated in glutamineImmunity 40, 692–705, May 15, 2014 ª2014 Elsevier Inc. 693
Figure 1. ASCT2 Deficiency Perturbs T Cell Homeostasis
Flow cytometry analyses of T cell populations in the spleen of age-matched Slc1a5+/+ (+/+) and Slc1a5–/– (–/–) mice (5 months old). Data are mean ± SD values of
multiple mice (each circle represents a mouse).
(A and B) Frequency (upper) and absolute number (lower) of CD4+ and CD8+ T cells (A) and the memory (CD44hiCD62Llo) and naive (CD44loCD62Lhi) CD4+
T cells (B).
(C) Frequency of IFN-g-producing Th1 and IL-17-producing Th17 cells (gated on CD4+CD44hiCD62Llo CD4+ T cells), as well as Treg cells (CD4+CD25+Foxp3+).
Data are representative of four independent experiments. *p < 0.05, **p < 0.01.
Also see Figures S1 and S2.
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ure S3E). This result, along with the competent expression
of SNAT1, in the Slc1a5–/– T cells (Figure S3C), suggests a
nonredundant role for ASCT2 in mediating naive CD4+ T cell
differentiation.
ASCT2 Deficiency Attenuates In Vivo Production of Th1
and Th17 Cells
To study the in vivo function of ASCT2 in regulating CD4+ T cell
differentiation and proinflammatory T cell responses, we em-
ployed a T cell adoptive transfer of colitis model, involving the
transfer of CD45RBhi naive CD4+ T cells to Rag1–/– mice. In the
absence of Treg cells, transferred naive CD4+ T cells are known
to differentiate into inflammatory Th1 and Th17 cells andmediate
colonic inflammation and cause body weight loss (Morrissey
et al., 1993). As expected, transfer of wild-type (WT) CD4+ naive
T cells to Rag1–/– mice induced severe body weight loss (Fig-
ure 3A). Importantly, this pathological phenotype was much
milder in recipient mice transferred with ASCT2-deficient naive
CD4+ T cells (Figure 3A). Consistently, the transferred Slc1a5–/–694 Immunity 40, 692–705, May 15, 2014 ª2014 Elsevier Inc.T cells displayed a severe defect in the production of the
IFN-g+ Th1 and IL-17+ Th17 cells (Figure 3B). We also detected
a population of IFN-g+IL-17+ double-positive T cells, which was
significantly reduced in the Slc1a5–/– T cell recipients (Figure 3B).
These results suggest a role for ASCT2 in regulating CD4+ T cell
differentiation in vivo under lymphopenic conditions.
Induction of the IFN-g-producing Th1 cells is a hallmark of in-
fections by intracellular bacterial pathogens, such as Listeria
monocytogenes (L. monocytogenes) (Kaufmann, 1993). We em-
ployed the L. monocytogenes model to examine the role of
ASCT2 in mediating Th1 cell responses against infections.
Infection of the WT mice with L. monocytogenes induced a
population of antigen-specific Th1 cells that produced IFN-g
upon restimulation with the Listerial antigen listeriolysin (LLO)
(Figure 3C). Although the L. monocytogenes-challenged
Slc1a5–/– mice also produced Th1 cells, this response was
profoundly reduced (Figure 3C). To examine the T cell-intrinsic
role of ASCT2, we adoptively transferred lymphocyte-deficient
Rag1–/– mice with Slc1a5+/+ or Slc1a5–/– T cells expressing
ovalbumin (OVA)-specific TCR (OT-II). After infection with
Figure 2. ASCT2 Is Dispensable for T Cell Proliferation but Is Required for Naive CD4+ T Cell Differentiation
(A and B) Proliferation assay (A) and IL-2 ELISA (B) of naive CD4+ T cells from age- and sex-matchedWT (+/+) and Slc1a5–/– (–/–) mice (8 weeks old), stimulated for
48 hr with the indicated doses of plate-bound anti-CD3 plus 1 mg/ml anti-CD28.
(C–F) Naive CD4+ T cells from Slc1a5+/+ and Slc1a5–/– mice were stimulated under Th1, Th2, Th17, or Treg cell skewing conditions and analyzed, on day 4, for
frequency of IFN-g+ Th1, IL-17+ Th17, and Foxp3+ Treg cells by flow cytometry (C and D), relative mRNA amount of the indicated genes by qPCR (E), and the
indicated secreted cytokines by ELISA (F). Data are representative of three (A, B, E, and F) or four (C and D) independent experiments with three or more mice per
group (mean ± SD in A, B, D, E, and F). *p < 0.05 and **p < 0.01.
Also see Figure S3.
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Figure 3. ASCT2 Regulates CD4+ T Cell Differentiation In Vivo
(A and B) Body-weight (BW) changes (percent of initial weight) (A) and frequency of the indicated effector T cells (percent of CD4+CD44+ cells) in the mesenteric
lymph nodes (B) of RAG1-deficient mice (6 weeks old) adoptively transferred with WT (+/+) or Slc1a5–/– (–/–) CD45RBhi CD4+ T cells (5 weeks after adoptive
transfer).
(C) Slc1a5+/+ or Slc1a5–/– mice were infected with L. monocytogenes for 7 days, and splenocytes were isolated and either not treated (None) or stimulated for 6 hr
with the LLO190–201 peptide (LLO) in the presence of momensin, followed by flow cytometry analysis of the frequency of CD4
+ T cells producing IFN-g (gated on
CD4+CD44+ cells).
(D) RAG1-deficient mice were adoptively transferred with CD4+ T cells from Slc1a5+/+ OT-II or Slc1a5–/– OT-II mice and infected with L. monocytogenes. On day 7
postinfection, splenocytes were isolated and either incubated withmedium (None) or stimulated with OVA323–339 and then subjected to intracellular IFN-g staining
and flow cytometry analysis of CD4+ T cells producing IFN-g (gated on CD4+CD44+ cells). Data are representative of three (A–C) or two (D) independent
experiments with least four mice per group (mean ± SD in B–D). *p < 0.05, **p < 0.01, ***p < 0.001.
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mice transferred with Slc1a5–/– OT-II T cells generated a more
reduced frequency of IFN-g-producing T cells than those trans-
ferred with the Slc1a5+/+ OT-II T cells (Figure 3D). Thus, ASCT2 is
required for CD4+ T cell differentiation under both lymphopenic
and antigen-stimulated conditions.
Slc1a5–/– Mice Are Refractory to EAE Induction
T cells have an important role in mediating the pathogenesis of
experimental allergic encephalomyelitis (EAE), an animal model
of multiple sclerosis (Miller et al., 2010). The finding that ASCT2
regulates T cell homeostasis and differentiation prompted us
to examine the role of ASCT2 in the regulation of EAE patho-
genesis. Immunization of Slc1a5+/+ mice with a myelin oligoden-
drocyte glycoprotein (MOG) peptide (MOG35–55), along with
injection with pertussis toxin, led to the induction of severe
EAE clinical scores (Figure 4A). Under the same conditions, the
Slc1a5–/– mice had much milder clinical scores (Figure 4A).
Hematoxylin and eosin (H&E) and luxol fast blue (LFB) staining
of the EAE-induced Slc1a5+/+ spinal cord sections revealed
extensive immune cell infiltration and demyelination, which
were profoundly weaker in the Slc1a5–/– spinal cord sections696 Immunity 40, 692–705, May 15, 2014 ª2014 Elsevier Inc.(Figure 4B). Parallel flow cytometry analyses revealed that the
EAE-resistant phenotype of the Slc1a5–/– mice was associated
with a substantial reduction in the number of central nervous
system (CNS)-infiltrating cells, including both CD4+ T cells and
CD11b+ myeloid cells, during the early stage (day 13) of EAE
induction (Figure 4C). The number of the IL-17-producing Th17
and IFN-g-producing Th1 cells was also reduced in the CNS
(Figure 4D), as well as in the draining lymph nodes (Figure 4E)
of the Slc1a5–/– mice.
To examine the T cell-intrinsic role of ASCT2 in regulating EAE
pathogenesis, we adoptively transferred Slc1a5+/+ or Slc1a5–/–
CD4+ T cells into lymphocyte-deficient Rag1–/– mice followed
by EAE induction in recipient mice. As expected, transfer of
Slc1a5+/+ CD4+ T cells into the Rag1–/– mice rendered the recip-
ient mice susceptible to EAE induction (Figure 4F). More impor-
tantly, mice transferredwithSlc1a5–/– CD4+ T cells had a delayed
onset and reduced clinical scores of EAE (Figure 4F). Consis-
tently, these recipient mice also had a drastically reduced num-
ber of CNS infiltrating immune cells, including both CD4+ T cells
and CD11b+ myeloid cells (Figure 4G). The number of both Th1
and Th17 cells was also low in the CNS of the Slc1a5–/– T cell re-
cipients (Figure 4H). Furthermore, during the early stage of EAE
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of the mutant recipient mice contained significantly lower fre-
quency and numbers of Th17 cells andmoderately lower number
of Th1 cells (Figure 4I). Considering their strikingly lower number
of CNS T cells, these mutant T cell-recipient mice clearly had an
overall reduction in both Th17 and Th1 cells. Collectively, these
results suggest that ASCT2 has a T cell-intrinsic role in mediating
EAE pathogenesis.
TCR Signal Stimulates Glutamine Uptake in an ASCT2-
Dependent Manner
ASCT2 has been implicated as an amino acid transporter that
mediates glutamine uptake in cell lines (Nicklin et al., 2009).
T cell activation triggers the induction of two glutamine
transporters, SNAT1 and SNAT2, which are associated with
enhanced glutamine uptake measured at 24 hr postactivation
(Carr et al., 2010). It is unclear whether these glutamine trans-
porters are required for TCR and CD28-stimulated glutamine
uptake and T cell functions. The role of ASCT2 in regulating naive
CD4+ T cell differentiation raised the intriguing question of
whether ASCT2 plays a role in glutamine uptake in naive
T cells and whether glutamine is required for CD4+ T cell differ-
entiation. We first examined whether glutamine uptake is altered
during the early phase of T cell activation. Stimulation of naive
T cells with anti-CD3 plus anti-CD28 rapidly promoted the
uptake of glutamine (Figure 5A). Moreover, the anti-CD3- and
anti-CD28-stimulated early phase glutamine uptake was com-
pletely blocked in the ASCT2-deficient T cells (Figure 5A). Pro-
longed T cell activation further enhanced the glutamine uptake,
and this late-phase induction of glutamine uptake was also crit-
ically dependent on ASCT2 (Figure 5A). The absolute concentra-
tion of intracellular glutamine was also stimulated by TCR and
CD28 signals in a mechanism that was largely dependent on
ASCT2 (Figure 5B). These findings suggest that naive CD4+
T cell activation is coupled with enhanced glutamine uptake, a
molecular process that is largely dependent on ASCT2.
We next examined the role of glutamine in the regulation of
naive CD4+ T cell differentiation. When activated in glutamine-
free medium, naive CD4+ T cells displayed a severe defect in
the generation of both Th1 and Th17 cells (Figure 5C). In
contrast, the production of Treg cells was normal in the absence
of glutamine (Figure 5C). Furthermore, addition of glutamine into
the cell culture led to the dose-dependent induction of Th1 and
Th17 cells, but the glutamine only had a slight effect on the
generation of Treg cells (Figures 5C and 5D). Glutamine also
had a stimulatory effect on the proliferation and survival of
T cells, although this functionwas detectedwith both the effector
T cells and Treg cells (Figure S4).
ASCT2Mediates TCR-Stimulated mTORC1 Activation in
Naive T Cells
To understand the signaling function of ASCT2, we examined
the TCR and CD28-mediated activation of three major families
of transcription factors, NF-kB, AP-1, and NFAT in Slc1a5+/+
and Slc1a5–/– T cells. ASCT2 deficiency did not appreciably
affect the activation of these transcription factors (Figure S5A).
Consistently, the TCR and CD28-stimulated phosphorylation
of several signaling factors, including the MAP kinases ERK,
JNK, and p38, IKK, and the IKK target IkBa, was largely compa-rable in the Slc1a5+/+ and Slc1a5–/– T cells (Figure S5B). There-
fore, ASCT2 is not required for the activation of several major
signaling pathways involved in T cell activation, which was in
line with the dispensability of ASCT2 in the proliferation and
IL-2 production.
Amino acids have a crucial role in the activation of the mTOR
signaling pathways (Jewell et al., 2013). Our finding that
ASCT2-mediated TCR and CD28-stimulated glutamine uptake
prompted us to examine whether ASCT2 is required for
mTOR activation by the TCR and CD28 signals. Stimulation of
T cells with anti-CD3 and anti-CD28 triggered the phosphoryla-
tion of ribosomal protein S6 (Figure 6A), a well-defined effector
molecule of the mTORC1 signaling pathway (Ruvinsky and
Meyuhas, 2006). The induction of S6 phosphorylation was
severely attenuated in the ASCT2-deficient T cells (Figure 6A).
Consistent with this result, TCR and CD28-stimulated phos-
phorylation of the S6 upstream kinase S6K1 was also defective
in the ASCT2-deficient T cells (Figure 6A). Because S6K1 is a
direct target of mTORC1 (Chi, 2012), this finding suggested
the requirement of ASCT2 in TCR and CD28-mediated activa-
tion of mTORC1. Indeed, ASCT2 deficiency also abrogated
the inducible phosphorylation of another known target of
mTORC1, 4EBP1 (Figure 6A). Meanwhile, ASCT2 was dispens-
able for TCR and CD28-stimulated phosphorylation of AKT
(Figure 6A), a target of mTORC2 and PI3 kinase (Chi, 2012).
Furthermore, attenuated mTORC1 activation was due to
reduced glutamine uptake, because TCR and CD28-stimulated
S6 phosphorylation could be restored in the presence of an
excessive amount of glutamine (Figure 6B). Addition of exces-
sive amounts of glutamine also rescued the defect of the
Slc1a5–/– T cells in differentiation into Th1 and Th17 cells (Fig-
ures 6C; Figure S5C).
To examine whether ASCT2 also regulated mTORC1 activa-
tion by other inducers, we analyzed the effect of ASCT2 defi-
ciency on tumor necrosis factor alpha (TNF-a)-stimulated
mTORC1 activation. Like anti-CD3 and anti-CD28, TNF-a stimu-
lated the phosphorylation of both S6 and the direct targets of
mTORC1, S6K1, and 4EBP1 (Figure S5D). TNF-a-stimulated
mTORC1 signaling was largely normal in the ASCT2-deficient
T cells. This finding suggests that the function of ASCT2 in medi-
ating mTORC1 activation is receptor specific. Recent studies
suggest that T cell activation induces the expression of the gluta-
mine transporters SNAT1 and SNAT2 (Carr et al., 2010), raising
the question of whether ASCT2 is still essential in effector
T cells. We addressed this question using Th1 and T17 effector
T cells generated through in vitro differentiation. ASCT2 was
partially required for the induction of S6 phosphorylation and
glutamine uptake in Th17 cells, but not in Th1 cells (Figure S5E).
These results suggest that ASCT2 predominantly regulates
glutamine uptake and mTORC1 signaling in naive CD4+ T cells,
although it also has a role in regulating these molecular events
in the Th17 effector T cells.
ASCT2 Is Required for Leucine Uptake and Metabolic
Activities
A recent study suggests that ASCT2-mediated glutamine uptake
in cancer cells is required for the uptake of leucine by a System L
amino acid transporter composed of CD98 (also called Slc3a2)
and Slc7a5 (Nicklin et al., 2009). The Slc7a5-CD98 complexImmunity 40, 692–705, May 15, 2014 ª2014 Elsevier Inc. 697
Figure 4. ASCT2 Has a T Cell-Intrinsic Role in Mediating EAE Pathogenesis
(A–E) EAE induction in Slc1a5+/+ and Slc1a5–/– mice (8 wk old). (A) Mean clinical scores. (B) H&E and Luxol Fast Blue (LFB) staining of spinal cord sections
from MOG35–55-immunized EAE mice (day 30 postimmunization) for visualizing immune cell infiltration and demyelination, respectively (arrows). Original
magnification, 3 100. (C–E) Flow cytometry analyses of the CD4+ T cell and the CD11b+ myeloid cell numbers in the CNS (C) and the absolute number and
frequency of the IL-17+ Th17 cells and IFN-g+ Th1 cells in the CNS (D) and draining lymph nodes (E) of day 13 EAE-induced Slc1a5+/+ and Slc1a5–/– mice.
(legend continued on next page)
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uptake, which is important for mTORC1 activation. Our finding
that ASCT2 was a major glutamine transporter mediating TCR
and CD28-stimulated glutamine uptake in naive CD4+ T cells
prompted us to test role of ASCT2 in leucine uptake under these
conditions. Stimulation of naive CD4+ T cells with anti-CD3 plus
anti-CD28 strongly induced leucine uptake, and this molecular
event indeed required ASCT2 (Figure 6D). The defect of the
Slc1a5–/– T cells in leucine uptake was not due to reduced
expression of Slc7a5 or CD98 (Figure S3C), thus supporting
the previous finding that the ASCT2-mediated glutamine uptake
might be required for leucine import by Slc7a5-CD98. Consis-
tently, addition of excessive amounts of exogenous leucine
rescued the defect of the ASCT2-deficient T cells in mTORC1
activation (Figure 6E). Exogenous leucine also rescued the
defect of the ASCT2-deficient T cells in Th17 cell differentiation,
albeit at a high concentration (Figure S6B). However, leucine
had an inhibitory effect on Th1 cell differentiation in both the
Slc1a5+/+ and Slc1a5–/– T cells (Figure S6B). Because exoge-
nous leucine efficiently rescued the mTORC1 signaling in
ASCT2-deficient T cells (Figure 6E), these data suggest that
leucine might regulate T cell differentiation via activation of
mTORC1 and additional mechanisms.
Glutamine has an important role in the regulation of glucose
uptake and anaplerosis (Kaadige et al., 2010; Kaadige et al.,
2009). We found that activation of naive CD4+ T cells by anti-
CD3 and anti-CD28 led to induction of glucose uptake (Fig-
ure 6F). Furthermore, the TCR and CD28-stimulated glucose
uptake was significantly inhibited, although not completely
blocked, in the ASCT2-deficient T cells. The TCR and CD28-
stimulated glucose uptake is known to be associated with
increased rate of glycolysis (Frauwirth et al., 2002). ASCT2 defi-
ciency also led to a reduction in lactate secretion by Slc1a5–/–
T cells as compared to Slc1a5+/+ T cells, consistent with a reduc-
tion in glycolysis (Figure 6G). Furthermore, exogenous glutamine
and leucine were able to rescue the defect of ASCT2-deficient
T cells in glycolysis (Figure S6C). We also found that TCR and
CD28 signals stimulated the expression of glucose transporter
1 (Glut1), which was severely attenuated in the Slc1a5–/–
T cells (Figure 6H). This finding was in agreement with the defect
of the Slc1a5–/– T cells in the activation of mTORC1 signaling,
which is known to mediate induction of Glut1 expression (Buller
et al., 2008; Taha et al., 1999; Taha et al., 1995). The mTORC1
signaling is also required for the expression of c-Myc, a tran-
scription factor that in turn is important for the cell growth and
various metabolic activities (Babcock et al., 2013; Kaadige
et al., 2010; Wall et al., 2008). ASCT2 deficiency partially in-
hibited the TCR and CD28-stimulated expression of c-Myc
(Figure 6H).
We next examined the effect of ASCT2 deficiency on oxidative
phosphorylation (OXPHOS), because this is one of the major
metabolic events regulated by glutamine (Kaadige et al., 2010).
OXPHOS is stimulated by TCR and CD28 signals and is required
for naive T cell activation (Chang et al., 2013). We assessed the(F–I) EAE induction in Rag1–/– mice (8 weeks old) adoptively transferred with Slc1
analyses of the CD4+ T cell and the CD11b+ myeloid cell numbers in CNS (G) a
and draining lymph nodes (I) of day 14 EAE-induced RAG1-deficient mice adopt
***p < 0.001.induction of OXPHOS by measuring oxygen consumption rate
(OCR), an indicator of OXPHOS (Chang et al., 2013). Stimulation
of naive CD4+ T cells with anti-CD3 plus anti-CD28 led to a rapid
increase in the OCR, followed by a steady rate (Figures 6I and
6J). Moreover, ASCT2 deficiency attenuated the initial burst
of oxygen consumption, although the OCR was similar in
Slc1a5+/+ and Slc1a5–/– T cells after longer time periods of stim-
ulation (Figures 6I and 6J). Collectively, these results indicate a
role for ASCT2 in the regulation of metabolic changes along
with T cell activation.
The CBM Complex Is Required for TCR-Stimulated
Glutamine Uptake and mTORC1 Activation
The results presented above suggested an ASCT2-dependent
mechanism that couples the TCR and CD28 signals to glutamine
uptake and mTORC1 activation. These findings also raised the
question of which of the TCR signaling pathways are involved
in this function. In this regard, the CBM complex, composed of
CARMA1, BCL10, and MALT1, is known to link the TCR and
CD28 proximal signals to downstream events, particularly acti-
vation of IKK and NF-kB (Blonska and Lin, 2009). We examined
the role of this signaling complex in the induction of glutamine
uptake and mTORC1 activation by TCR and CD28. Genetic defi-
ciency in CARMA1, BCL10, or MALT1 severely attenuated the
induction of glutamine uptake by anti-CD3 plus anti-CD28 (Fig-
ure 7A). Meanwhile, loss of the major CBM target, IKKb, had
no effect on the induction of glutamine uptake (Figure 7A).
Consistent with these results, genetic deficiency in any of the
CBM components, but not IKKb, attenuated the induction of
S6 phosphorylation by anti-CD3 plus anti-CD28 (Figure 7B).
The role of CARMA1 in regulating mTORC1 activation was also
demonstrated with a human Jurkat T cell variant, JPM50.6
(Wang et al., 2002), deficient in CARMA1 expression (Figure 7C).
These data suggested a function of the CBM complex that con-
nects the TCR and CD28 signals to the induction of glutamine
uptake and mTORC1 activation independently of the down-
stream IKKb.
To further confirm that the CBM regulates mTORC1 activation
via the induction of glutamine uptake, we examined whether
excessive leucine could rescue the mTORC1 signaling defect
of the CARMA1-deficient T cells, as seen in ASCT2-deficient
T cells. Indeed, the exogenous leucine was able to restore
TCR and CD28-stimulated phosphorylation of S6 and its kinase
S6K1 (Figure S7A). Similar to ASCT2-deficient T cells, CARMA1-
and Bcl10-deficient T cells displayed a defect in TCR and CD28-
stimulated glucose uptake (Figure S7B), further emphasizing the
role of the CBM complex in mediating the induction of metabolic
activities during T cell activation.
To define the mechanism by which the CBM complex regu-
lates glutamine uptake and mTORC1 activation, we examined
the role of CARMA1 in regulating ASCT2 expression. CARMA1
deficiency only moderately reduced the basal level of ASCT2
mRNA; however, the loss of CARMA1 dramatically inhibited
the TCR and CD28-stimulated ASCT2 mRNA expressiona5+/+ or Slc1a5–/– CD4+ T cells. (F) Mean clinical scores. (G–I) Flow cytometric
nd the absolute number and frequency of Th17 and Th1 cells in the CNS (H)
ively transferred with Slc1a5+/+ or Slc1a5–/– CD4+ T cells. *p < 0.05, **p < 0.01,
Immunity 40, 692–705, May 15, 2014 ª2014 Elsevier Inc. 699
Figure 5. TCR and CD28-Stimulated Glutamine Uptake Requires ASCT2 and Regulates CD4+ T Cell Differentiation
(A) Glutamine uptake analysis of Slc1a5+/+ or Slc1a5/ naive CD4+ T cells, stimulated for 30 min with anti-CD3 and anti-CD28 mixed with a crosslinking anti-
hamster immunoglobulin G (left) or for 20 hr with plate-bound anti-CD3 and anti-CD28 (right).
(B) Intracellular glutamine analysis of Slc1a5+/+ or Slc1a5/ naive CD4+ T cells, stimulated for 20 hr with plate-bound anti-CD3 and anti-CD28.
(C and D) Flow cytometry analysis of Th1, Th17, and Treg cells generated thorough in vitro differentiation of Slc1a5+/+ or Slc1a5–/– naive CD4+ T cells (for
4 days) under the polarizing conditions described in Figure 2 in glutamine-free medium supplemented with the indicated amount of L-glutamine. Data are
representative of three (A and B) or four (C and D) independent experiments with at least three mice per group (mean ± SD in A and C). *p < 0.05, **p < 0.01,
***p < 0.001.
Also see Figure S4.
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Regulation of CD4+ T Cell Differentiation by ASCT2(Figure 7D). The CARMA1 deficiency did not significantly affect
the induction of other amino acid transporters, including
SNAT1, SNAT2, Slc7a5, and CD98 (Figure 7D). These results
explain the defect of the CARMA1-deficient T cells in the late-700 Immunity 40, 692–705, May 15, 2014 ª2014 Elsevier Inc.phase induction of glutamine uptake. In addressing the mecha-
nism by which CBM regulates the early-phase glutamine uptake,
we found that CARMA1 physically interacted with ASCT2 (Fig-
ure 7E; Figure S7C). In the absence of CARMA1, Bcl10 and
Figure 6. ASCT2 Mediates TCR and CD28-
Stimulated mTORC1 Activation in Naive
CD4+ T Cells
(A and B) IB analyses of the indicated phosphor-
ylated (P-) and total proteins in whole-cell lysates
of Slc1a5+/+ or Slc1a5–/– naive CD4+ T cells,
stimulated with anti-CD3 and anti-CD28 with the
crosslinking method in regular RPMI 1640medium
(A) or glutamine-free medium supplemented with
the indicated amount of L-glutamine (B).
(C) Flow cytometry analysis of Th1, Th17, and Treg
cells generated thorough in vitro differentiation of
Slc1a5+/+ or Slc1a5–/– naive CD4+ T cells (for
4 days) under the Th1 or Th17 polarizing condi-
tions in glutamine-free medium supplemented
with the indicated amount of L-glutamine.
(D) Leucine uptake analysis of Slc1a5+/+ or
Slc1a5/ naive CD4+ T cells, either not treated
(NT) or stimulated for 20 hr with plate-bound anti-
CD3 and anti-CD28.
(E) IB analysis of the indicated proteins in whole-
cell lysates of Slc1a5+/+ or Slc1a5–/– naive CD4+
T cells that were either not (–) or stimulated (+) with
anti-CD3 and anti-CD28 for 30 min.
(F) 2-deoxyglucose uptake analysis of the cells
described in (D).
(G) Slc1a5+/+ or Slc1a5–/– naive CD4+ T cells were
either not treated (NT) or stimulated with plate-
bound anti-CD3 plus anti-CD28 for 20 hr in a
96-well plate. Lactate concentration in the cul-
ture medium was measured and calculated as
described in the Supplemental Experimental
Procedures.
(H) IB analyses of Gult1 and c-Myc in whole-cell
lysates of the Slc1a5+/+ or Slc1a5–/– naive CD4+
T cells described in (D).
(I and J) Oxygen consumption in Slc1a5+/+
or Slc1a5–/– naive CD4+ T cells, either not
treated (NT) or stimulated with plate-bound anti-
CD3 plus anti-CD28 for 20 hr in a 96-well
plate. Fluorescence-probe intensity was mea-
sured for the indicated time periods and is
presented as relative fluorescence unit (RFU) per 106 cells (I). The increase rate of oxygen consumption was calculated at early phase (0–60 min) and late
phase (60–120 min) (J).
Data are representative of three independent experiments with at least three mice per group. *p < 0.05, **p < 0.01, ***p < 0.001.
Also see Figures S5 and S6.
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response to TCR and CD28 stimulation, ASCT2 rapidly aggre-
gated and colocalized with the TCR complex (Figure 7F). This
molecular event was dependent on CARMA1, because it did
not occur in the CARMA1-deficient cells. Although precisely
how the CBM complex activates ASCT2-mediated glutamine
uptake requires additional studies, we found that the protease
activity of MALT1 was required because a MALT1 inhibitor,
z-VRPR-fmk (Rebeaud et al., 2008), blocked the TCR and
CD28-stimulated glutamine uptake (Figure S7D) and the phos-
phorylation of S6 and S6K1 (Figure S7E). These data provide
additional clues to the mechanism by which CARMA1 regulates
ASCT2 function and glutamine uptake.
DISCUSSION
Glutamine has been implicated as a nutrient with immunomodu-
latory functions, but the role of glutamine in regulating T cell func-tion and themechanism by which glutamine uptake is coupled to
TCR signaling have been unclear. The existence of several
potential glutamine transporters makes this system particularly
complex. Here we have obtained genetic evidence that ASCT2
is crucial for mediating TCR-stimulated glutamine uptake in
naive T cells. We found that ASCT2 was required for TCR and
CD28-stimulated activation of mTORC1 signaling, although it
was dispensable for the activation of several other T cell activa-
tion pathways, including the MAP kinase pathways and the IKK
pathway. Consistently, the ASCT2 deficiency did not compro-
mise the initial T cell activation processes, including proliferation
and IL-2 production. Meanwhile, loss of ASCT2 attenuated the
differentiation of naive CD4+ T cells to Th1 and Th17 cells and
influenced the in vivo T cell responses. In contrast, ASCT2 was
completely dispensable for the generation of Treg cells from
naive CD4+ T cells. Treg cell differentiation also occurred nor-
mally under glutamine-free conditions. These results are in
agreement with the previous finding that mTORC1 is requiredImmunity 40, 692–705, May 15, 2014 ª2014 Elsevier Inc. 701
Figure 7. CBM Complex Is Required for
TCR and CD28-Stimulated Glutamine Up-
take and mTORC1 Activation
(A) Glutamine uptake analysis of naive CD4+ T cells
derived from the indicated genetic ablation and
their WT control mice, either not treated (NT) or
stimulated for 30min with anti-CD3 and anti-CD28
with the crosslinking method.
(B) IB analysis of phosphorylated (P-) and total S6
in whole-cell lysates of the indicated genetic
ablation and WT control naive CD4+ T cells stim-
ulated with anti-CD3 and anti-CD28 as in (A).
(C) IB analyses of phosphorylated (P-) and total S6
and S6K in whole-cell lysates of parental Jurkat
cells and the CARMA1-deficient JPM50.6 cells
stimulated with anti-CD3 and anti-CD28.
(D) qPCR analysis of the relative mRNA amount of
the indicated genes in Card11+/+ or Carma1–/–
naive CD4+ T cells, stimulated for 20 hr with plate-
bound anti-CD3 and anti-CD28.
(E)HEK293cellswere transfectedwithMyc-tagged
CARMA1 or Myc-tagged Bcl10 in the absence (–)
or presence (+) of HA-tagged ASCT2. ASCT2 was
isolated by IP with anti-HA, and its associated
CARMA1 and Bcl10 were detected by anti-Myc IB
(upper). The expression of ASCT2, CARMA1, and
Bcl10 was monitored by direct IB (lower).
(F) Jurkat cells and JPM50.6 cells were stimulated
for 15 min with anti-CD3 and anti-CD28 and were
stained with rabbit anti-ASCT2 or mouse anti-
TCRb, followed by incubation with Alexa Fluor
488-labeled goat anti-rabbit or Alexa Fluor 647-
labeled goat anti-mouse secondary antibodies.
The subcellular localization of ASCT2 (green),
TCR-b (red) and nucleus (blue) were visualized by
confocal fluorescent microscopy. Scale bar rep-
resents 5 mm.
Data are representative of three independent ex-
periments with three or more mice per group
(mean ± SD in A and D). *p < 0.05, **p < 0.01.
Also see Figure S7.
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Regulation of CD4+ T Cell Differentiation by ASCT2for the generation of Th1 and Th17 cells, but not Treg cells (Del-
goffe et al., 2009).
Our data revealed that ASCT2 was particularly important for
glutamine uptake and mTORC1 activation in naive T cells. In
effector T cells, ASCT2 was either completely or partially
dispensable for these cellular events. Because T cell activation
is associated with the transcriptional induction of several other
glutamine transporters, including SNAT1 and SNAT2 (Carr
et al., 2010), it is possible that ASCT2 is functionally redundant
with other glutamine transporters in effector T cells. Consistent
with this hypothesis, we found that the ASCT2 deficiency did
not affect the induction of SNAT1 or SNAT2. The ASCT2 ablation
also did not significantly affect the TCR and CD28-stimulated702 Immunity 40, 692–705, May 15, 2014 ª2014 Elsevier Inc.expression of Slc7a5 and CD98, compo-
nents of a major leucine transporter in
T cells (Sinclair et al., 2013). However,
the TCR and CD28-stimulated leucine
uptake was attenuated in the ASCT2-
deficient T cells, a finding that is
consistent with a prior report that theASCT2-mediated glutamine uptake in cancer cells is required
for the uptake of leucine by the Slc7a5-CD98 amino acid trans-
porter (Nicklin et al., 2009). Compared to glutamine, leucine
was more efficient in rescuing mTORC1-activation defect of
ASCT2-deficient T cells, supporting the idea that glutamine
might regulate mTORC1 signaling via promoting leucine uptake
(Nicklin et al., 2009). Previous studies suggest that amino acids
activate mTORC1 by inducing its translocation to the lysosomal
membrane (Sancak et al., 2010) and that glutamine and leucine
might cooperate in this pathway of mTORC1 activation (Dura´n
et al., 2012). Future studies will examine whether ASCT2-medi-
ated glutamine uptake in T cells both promotes leucine uptake
and synergizes with leucine in the activation of mTORC1.
Immunity
Regulation of CD4+ T Cell Differentiation by ASCT2Activation of mTORC1 by TCR and CD28 signals is known to
involve AKT, which is activated by both mTORC2 and the PI3
kinase-activated kinase PDK1 (Chi, 2012;Waickman andPowell,
2012). We found that the ASCT2 deficiency attenuated the TCR
and CD28-stimulated mTORC1 activation without inhibiting AKT
activation. This result suggests the requirement of two coordi-
nated signals, the AKT signal and the amino acid (leucine and
glutamine) signal, in the activation of mTORC1 by the TCR and
CD28 stimuli. In further support of this idea, we found that the
TCR and CD28 ligation stimulated rapid glutamine uptake, as
well as leucine uptake, in naive T cells in an ASCT2-dependent
manner. Whereas leucine uptake might be indirectly regulated
by the ASCT2-mediated glutamine uptake (Nicklin et al., 2009),
how the TCR and CD28 signals stimulate the rapid glutamine
uptake via a ASCT2-dependent manner is still not quite clear.
Nevertheless, our data suggest a crucial role for the CBM sig-
naling complex. Ablation of any of the three CBM components
severely attenuated TCR andCD28-stimulated glutamine uptake
andmTORC1 activation. To date, the best-known function of the
CBM complex is to mediate TCR and CD28-stimulated activa-
tion of IKK and its downstream transcription factor NF-kB
(Thome et al., 2010). IKK was dispensable for the induction of
glutamine uptake and mTORC1 activation in T cells. It is thus
likely that a different mechanism mediates the function of the
CBM complex in the regulation of mTORC1 activation. Our
data suggested that the CBM complex is required for TCR and
CD28-stimulated expression of ASCT2. In addition, CARMA1
physically interacted with ASCT2. In response to TCR and
CD28 crosslinking, ASCT2 formed aggregates that are colocal-
ized with the TCR complex. Moreover, these molecular events
were dependent on CARMA1. Although precisely how the
CBM complex mediates activation of ASCT2-mediated gluta-
mine uptake remains to be further studied, we found that the
protease activity of MALT1 is required for TCR and CD28-
stimulated glutamine uptake and mTORC1 signaling. These
findings provide important clues to the mechanism by which
the TCR and CD28 signals stimulate ASCT2-dependent gluta-
mine uptake.
A hallmark of T cell activation is the association with metabolic
changes (MacIver et al., 2013).We found that stimulation of naive
CD4+ T cells with the anti-CD3 and anti-CD28 antibodies trig-
gered a number of metabolic activities, including the induction
of glucose uptake and glycolysis, upregulation of Glut1 and
c-Myc expression, as well as increased OXPHOS. Consistent
with the important role of glutamine in promoting these meta-
bolic activities, these activities were all compromised, although
not completely blocked, in the Slc1a5–/– T cells. However, how
ASCT2 regulates metabolic activities and whether these func-
tions are attributed to the glutamine and leucine uptake warrant
further studies. Nevertheless, it is likely that some of these meta-
bolic events might involve the ASCT2-dependent activation of
mTORC1. For example, mTORC1 is known to mediate induction
of both Glut1 and c-Myc, which in turn are important for various
other metabolic activities (Babcock et al., 2013; Buller et al.,
2008; Kaadige et al., 2010; Taha et al., 1999; Taha et al., 1995).
However, glutamine and leucine might also regulate mTORC1-
independent functions in T cells. We found that addition of
excessive leucine into the culture medium efficiently rescued
the defect of theSlc1a5–/– T cells inmTORC1 signaling; however,it required a much higher concentration of leucine to rescue the
differentiation of CD4+ T cells. Future studies will further investi-
gate how glutamine regulates the differentiation and effector
functions of T cells.
Our finding that ASCT2 deficiency had no obvious effect on
TCR and CD28-stimulated IL-2 production and proliferation
was seemingly surprising. Meanwhile, previous gene targeting
studies have also revealed that mTORC1 is dispensable for
IL-2 induction and partially dispensable for T cell proliferation
(Delgoffe et al., 2011). Thymocyte development and T cell ho-
meostasis are also normal in the absence of mTORC1 (Delgoffe
et al., 2009). LikemTORC1, ASCT2was particularly important for
the differentiation of CD4+ T cells to Th1 and Th17 cells. The lack
of a notable effect of ASCT2 deficiency on TCR and CD28-stim-
ulated naive T cell proliferation might also be due to the partial
inhibition, instead of complete blockade, of mTORC1 activation
and metabolic activities in the ASCT2-deficient T cells. Although
ASCT2 was crucial for TCR and CD28-stimulated initial gluta-
mine uptake, it was partially dispensable for the uptake of both
glutamine and leucine after longer periods of cell stimulation.
TCR and CD28-stimulated glucose uptake, glycolysis, and
Myc expression were also partially retained in the Slc1a5–/–
T cells. Clearly, how precisely ASCT2 regulates T cell functions
requires further studies. Oxygen consumption, although not
glycolysis, is important for naive T cell activation and proliferation
(Chang et al., 2013). Our data suggest that ASCT2 deficiency
attenuated the initial burst of the oxygen consumption but only
had a minor effect on the sustained OCR. This result might
also explain why the proliferation of T cells was not appreciably
affected by the ASCT2 deficiency.
In summary, our data establish ASCT2 as a glutamine trans-
porter that regulates CD4+ T cell differentiation and T cell-medi-
ated immunity against infections and self-antigens. Our findings
also suggest a role for ASCT2 in coupling the TCR and CD28
signals to the induction of glutamine and leucine uptake and
mTORC1 activation, thus providing insight into the dynamic
interplay between the antigen-stimulated signal and the environ-
mental signals in the control of T cell function. Finally, we have
identified a function of the CBM complex in mediating the induc-
tion of glutamine uptake and mTORC1 activation, which might
involve activation of the glutamine transporter ASCT2.EXPERIMENTAL PROCEDURES
Mice
Slc1a5–/– mice (in C57BL/63 129/sv genetic background) were generated by a
conventional gene-targeting strategy, in which coding exons 2 and 4 were
replaced with a lacZ–neomycin-resistance cassette (Taconic, Figure S1).
Heterozygous Slc1a5+/– mice were bred to generate age- and sex-matched
homozygous ASCT2-ablated (Slc1a5–/–) and WT (Slc1a5+/+) mice, which
were used in the experiments at the indicated ages. Genotyping PCR and
RT-PCR primers are listed in Table S1. The TCR transgenic OT-II mice and
the lymphocyte-deficient Rag1–/– deficient mice were from Jackson Labora-
tory. Ikbkb-floxed mice, provided by Dr. Manolis Pasparakis (University of
Cologne), were crossed with Cd4-cre mice (Jackson Laboratory) to produce
T cell-conditional Ikbkb–/– mice. Card11–/– mice (C57BL/6 3 129/sv genetic
background) were provided by Dr. Josef Penninger (Austria Academy of Sci-
ences), Bcl10–/– mice were provided by Dr. Stephan Morris (St Jude Children’s
Research Hospital), and the Malt1–/– mice were provided by Dr. Vishva Dixit
(Genentech). Mice were maintained in specific pathogen-free facility of The
University of Texas MD Anderson Cancer Center, and all animal experimentsImmunity 40, 692–705, May 15, 2014 ª2014 Elsevier Inc. 703
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Animal Care and Use Committee.
Nutrient Uptake
Glutamine, leucine, phenylalanine, and glucose uptake were essentially as
described (Carr et al., 2010; Sinclair et al., 2013). Following activation
by anti-CD3 plus anti-CD28, the CD4+ T cells were resuspended (4 3 107
cells/ml) in a serum- and glutamine-free RPMI 1640 medium (for glutamine
uptake), Hank’s balanced-salt solution (for leucine uptake), or glucose-free
RPMI 1640 (for glucose uptake). We carefully added 50 ml of the cell suspen-
sion (2 3 106 cells) to the top layer of a 0.7 ml microfuge tube preloaded with
25 ml 8% sucrose and 20% perchloric acid (bottom layer), 200 ml 1-bromodo-
decane (middle layer), and 50 ml uptake medium containing 2 mCi L-2,3,4-[3H]
glutamine, 1 mCi L-[3H]leucine, 1 mCi L-[3H]phenylalanine or 2 mCi [3H]2-deox-
yglucose. Cells were allowed to take up the radiolabeled nutrient for 10 min at
room temperature and then spun through the bromododecane into the
sucrose-perchloric acid layer to stop the reaction and separate the cells
from unincorporated 3H-labeled nutrient. The sucrose-perchloric acid layer,
containing the T cells, was collected for liquid scintillation assay to quantify
the radiolabeled nutrient taken up by the T cells.
Statistical Analysis
A two-tailed unpaired t test was done with the Prism software. p values of less
than 0.05 were considered significant, and the level of significance was further
defined at levels of *p < 0.05, **p < 0.01, ***p < 0.001.
SUPPLEMENTAL INFORMATION
Supplemental Information includes seven figures, one table, and Supple-
mental Experimental Procedures and can be found with this article online at
http://dx.doi.org/10.1016/j.immuni.2014.04.007.
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